Biologic approvals ranged from gene therapies for hemophilia A to a cellular therapy to treat type 1 diabetes.
Biologic product approvals in 20231 ran the gamut, including 2 new therapies to treat hemophilia A, a gene therapy for pediatric Duchenne muscular dystrophy, and the first orally administered fecal microbiota product to treat recurrent C difficile infection. And on December 8, the FDA approved 2 new therapies—the first of their kind—to treat sickle cell disease, an inherited blood disorder that disproportionately affects Black or African American individuals.
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.